<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388385</url>
  </required_header>
  <id_info>
    <org_study_id>10488/19.04.2016</org_study_id>
    <nct_id>NCT03388385</nct_id>
  </id_info>
  <brief_title>Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD</brief_title>
  <official_title>The Effects of a Single Intravenous Iron Upon Vascular Endothelium and Some Parameters of Oxidative Stress in Patients With Non-dialysis Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carol Davila University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>S.C. Sanador S.R.L</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carol Davila University of Medicine and Pharmacy</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of acute intravenous iron
      administration on the endothelial function in non-dialysis Chronic Kidney Disease stages
      G3-G5 patients with anemia and iron deficiency, in relation to changes in oxidative and
      nitrosative status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on endothelial function</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Description of the endothelial function variation (changing in flow-mediated vasodilatation (FMD) endothelium-dependent, and also in serum sICAM-1, sVCAM-1 and nitric oxide metabolism parameters ) after administration of a single intravenous dose of iron versus a control solution, in CKD non-dialysis patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Description of some free radicals production's markers (lipid peroxidation and carbonyl stress assessment) and in antioxidant system in plasma markers variation after administration of a single intravenous iron dose versus a control solution, in non-dialysis CKD subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between endothelial dysfunction and oxidative stress markers</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Evaluation of correlations between changes in oxidative stress parameters and endothelial function after a single intravenous iron administration compared to a control solution in non-dialysis CKD subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Anemia</condition>
  <condition>Iron Toxicity</condition>
  <condition>Oxidative Stress</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 0.9% Intravenous Solution</intervention_name>
    <description>Physiologic saline infusion will be infused in day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <other_name>Physiologic saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject</intervention_name>
    <description>Ferric carboxymaltose will be infused in day 2.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <other_name>Ferric carboxymaltose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease stages G3-G5 (defined according to KDIGO criteria);

          -  Anemia (defined according to KDIGO criteria) and iron deficiency defined as serum
             ferritin &lt; 100 ng/mL and/or TSAT &lt; 20% (KDIGO).

        Exclusion Criteria:

          -  contraindications of intravenous iron therapy: iron allergy, active infection,
             hemochromatosis, iron overload (serum ferritin &gt; 500 ng/mL and/or transferrin
             saturation &gt; 50%);

          -  treatment with iron and erythropoiesis-stimulating agents (at the time of recruitment
             and 6 months previously);

          -  active smoker status;

          -  antioxidant food supplements treatment in the last 3 months;

          -  clinically manifest bleeding;

          -  another cause of anemia (hemoglobinopathies, vitamin B12 and/or folic acid deficiency
             suggested by the megaloblastic peripheral blood smears's appearance, multiple myeloma
             and other paraproteinemias);

          -  severe anemia (Hb &lt; 7 g/dl);

          -  baseline FMD &lt; 7% (the existence of atherosclerosis which limits arterial reactivity);

          -  cancer (currently or in the past 6 months);

          -  hepatopathies (increased serum transaminases ≥ 3 x normal value) or hepatic impairment
             ≥ grade Child B;

          -  autoimmune disorders or significant inflammation (as defined by C-reactive protein &gt; 5
             mg/L);

          -  pregnancy or lactation;

          -  participation in other clinical trials over the upast 3 months;

          -  patient unwillingness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Mircescu, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Carol Davila University of Medicine and Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Capusa, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Carol Davila University of Medicine and Pharmacy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana-Maria Mehedinti, Teach. Assist.</last_name>
    <phone>004740240981</phone>
    <email>ana_mehe@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Capusa, Assoc. Prof.</last_name>
    <phone>0040722409832</phone>
    <email>ccalexandr@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>&quot;Dr. Carol Davila&quot; Teaching Hospital of Nephrology</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana-Maria Mehedinti</last_name>
      <phone>004740240981</phone>
      <email>ana_mehe@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>December 24, 2017</last_update_submitted>
  <last_update_submitted_qc>December 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carol Davila University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Ana-Maria Mehedinti</investigator_full_name>
    <investigator_title>Teaching Assistent</investigator_title>
  </responsible_party>
  <keyword>CKD, anemia, iron, endothelial dysfunction, oxidative stress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

